Exact Sciences (EXAS) Expected to Announce Quarterly Earnings on Wednesday

Exact Sciences (NASDAQ:EXAS) is expected to announce its earnings results after the market closes on Wednesday, February 19th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $701.45 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Exact Sciences Price Performance

NASDAQ:EXAS opened at $51.06 on Wednesday. The firm has a fifty day simple moving average of $56.93 and a 200 day simple moving average of $60.20. Exact Sciences has a 1-year low of $40.62 and a 1-year high of $79.62. The stock has a market capitalization of $9.45 billion, a PE ratio of -43.64 and a beta of 1.24. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a report on Monday, January 13th. Bank of America cut their price target on Exact Sciences from $75.00 to $72.00 and set a “buy” rating for the company in a report on Friday, December 13th. Benchmark reaffirmed a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. Evercore ISI cut their price target on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein raised their price target on Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.